CareCloud Earnings Call Transcripts
Fiscal Year 2026
-
Q1 2026 revenue rose 13% year-over-year to $31.3M, with recurring revenue growth and strong AI traction. Profitability was impacted by acquisition integration, but guidance for 2026 is reaffirmed, with margin improvement expected as costs decline and AI efficiencies scale.
Fiscal Year 2025
-
2025 saw record revenue, profitability, and free cash flow, driven by strategic acquisitions and the launch of a flagship AI platform. Guidance for 2026 projects continued growth, margin expansion, and further AI integration, with all acquisitions funded from free cash flow.
-
Stratus AI Desk Agent modernizes patient phone access by autonomously handling up to 80% of inbound calls, reducing staff workload and improving patient satisfaction. The system is HIPAA compliant, highly customizable, and delivers significant cost savings and ROI, with rapid implementation and multilingual support.
-
Q3 2025 saw 9% revenue growth, strong cash flow, and major acquisitions expanding into the hospital and analytics markets. AI-driven solutions and disciplined capital allocation drove improved margins and raised full-year guidance.
-
Reported first-ever positive GAAP EPS and strong net income growth, driven by operational efficiency and AI innovation. Reaffirmed 2025 guidance, expanded AI product adoption, and entered the critical access hospital market, while maintaining robust cash flow and pursuing accretive M&A.
-
Q1 2025 saw revenue rise to $27.6M and a return to profitability, driven by AI innovation, cost discipline, and accretive acquisitions. Guidance for 2025 is reaffirmed, with continued investment in AI and a strengthened capital structure.
-
A healthcare technology platform leverages proprietary tech and AI to serve 40,000 providers, focusing on cost-efficient growth through acquisitions and innovation. Recent financials show record free cash flow, reduced debt, and resumed acquisitions after a three-year pause.
Fiscal Year 2024
-
Record profitability achieved in 2024, with net income and free cash flow at all-time highs, driven by operational efficiency and AI innovation. Series A preferred stock conversion simplified the capital structure, and 2025 guidance projects revenue growth, higher EBITDA, and first positive EPS since IPO.
-
Record free cash flow and a return to profitability enabled full repayment of debt and the resumption of preferred dividends in 2025. AI-driven solutions and cost reductions drove margin expansion, while recurring revenue remained stable despite medSR headwinds.
-
Returned to profitability in Q2 2024 with positive GAAP net income and strong free cash flow, driven by cost reductions, AI product innovation, and significant debt repayment. CareCloud Wellness and cross-sell/upsell initiatives fueled growth, while medSR remained soft.